Found: 24
Select item for more details and to access through your institution.
Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022.
- Published in:
- JAMA Health Forum, 2023, v. 4, n. 1, p. e225218, doi. 10.1001/jamahealthforum.2022.5218
- By:
- Publication type:
- Article
Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017.
- Published in:
- JAMA Health Forum, 2022, v. 3, n. 5, p. e221158, doi. 10.1001/jamahealthforum.2022.1158
- By:
- Publication type:
- Article
Estimated Medicare Part D Savings From Generic Drugs With a Skinny Label.
- Published in:
- Annals of Internal Medicine, 2024, v. 177, n. 6, p. 833, doi. 10.7326/M23-3212
- By:
- Publication type:
- Article
Evaluation of confounding in epidemiologic studies assessing alcohol consumption on the risk of ischemic heart disease.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Transparency of Regulatory Data across the European Medicines Agency, Health Canada, and US Food and Drug Administration.
- Published in:
- Journal of Law, Medicine & Ethics, 2021, v. 49, n. 3, p. 456, doi. 10.1017/jme.2021.67
- By:
- Publication type:
- Article
Optimiser les données accessibles dans le portail de renseignements cliniques de Santé Canada.
- Published in:
- Canadian Medical Association Journal (CMAJ), 2021, v. 193, n. 41, p. 1618, doi. 10.1503/cmaj.210877-f
- By:
- Publication type:
- Article
Federal Trade Commission Actions on Prescription Drugs, 2000-2022.
- Published in:
- JAMA: Journal of the American Medical Association, 2024, v. 331, n. 23, p. 2029, doi. 10.1001/jama.2024.5737
- By:
- Publication type:
- Article
Gauging the Value of Top-Selling Drugs in Medicare—Reply.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 330, n. 7, p. 665, doi. 10.1001/jama.2023.10961
- By:
- Publication type:
- Article
Added Therapeutic Benefit of Top-Selling Brand-name Drugs in Medicare.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 329, n. 15, p. 1283, doi. 10.1001/jama.2023.4034
- By:
- Publication type:
- Article
Estimated Medicare Part B Savings From Inflationary Rebates.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 329, n. 1, p. 89, doi. 10.1001/jama.2022.20189
- By:
- Publication type:
- Article
Recent Trends in Prescription Drug Launch Prices-Reply.
- Published in:
- JAMA: Journal of the American Medical Association, 2022, v. 328, n. 13, p. 1352, doi. 10.1001/jama.2022.13828
- By:
- Publication type:
- Article
Trends in Prescription Drug Launch Prices, 2008-2021.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Medicare Part D Spending on Single-Enantiomer Drugs Versus Their Racemic Precursors.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Systematic overview of Freedom of Information Act requests to the Department of Health and Human Services from 2008 to 2017.
- Published in:
- Research Integrity & Peer Review, 2019, v. 4, n. 1, p. N.PAG, doi. 10.1186/s41073-019-0086-2
- By:
- Publication type:
- Article
Demographic Characteristics of Participants in Trials Essential to US Food and Drug Administration Vaccine Approvals, 2010–2020.
- Published in:
- 2022
- By:
- Publication type:
- Letter
Medicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment Agencies.
- Published in:
- 2019
- By:
- Publication type:
- letter
Timeliness of Postmarket Studies for New Pharmaceuticals Approved Between 2009 and 2012: a Cross-Sectional Analysis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review.
- Published in:
- JAMA Network Open, 2021, v. 4, n. 5, p. e215731, doi. 10.1001/jamanetworkopen.2021.5731
- By:
- Publication type:
- Article
Frequency of Approval and Marketing of Biosimilars With a Skinny Label and Associated Medicare Savings.
- Published in:
- 2023
- By:
- Publication type:
- journal article
Speed, Evidence, and Safety Characteristics of Vaccine Approvals by the US Food and Drug Administration.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Confidentiality Orders and Public Interest in Drug and Medical Device Litigation.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Medicare Spending and Potential Savings on Brand-Name Drugs With Available Generic Substitutes Excluded by 2 Large Pharmacy Benefit Managers, 2012 Through 2015.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Use of Efficiency Frontiers to Align Prices and Clinical Benefits of Biologic Therapies for Plaque Psoriasis.
- Published in:
- JAMA Dermatology, 2024, v. 160, n. 4, p. 409, doi. 10.1001/jamadermatol.2023.6236
- By:
- Publication type:
- Article
Optimizing the data available via Health Canada's clinical information portal.
- Published in:
- 2021
- By:
- Publication type:
- journal article